Stark

FULGENT GENETICS, INC. (NASDAQ: FLGT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulgent Genetics, Inc. (NASDAQ: FLGT)

Retrieved on: 
화요일, 11월 8, 2022
Genetics, GLOBE, Battle of Saint-Fulgent, Genetic testing, Health, Investment, Remuneration, Disclosure, Company, Justice, Office of Inspector General, U.S. Department of Health and Human Services, Anti-Kickback Statute, Stark, Stark Law, The Legal 500, SEC, Advertising, NASDAQ, News, Securities Exchange Act of 1934, Reward, District court, U.S. Department of Justice Office of Legislative Affairs, Court, Medicare, Physician, Patient, NEW, Labour government, Central District, COVID-19, Tobacco, Pharmaceutical industry, Security (finance)

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Fulgent, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
  • If you purchased Fulgent securities, and/or would like to discuss your legal rights and options please visit Fulgent Genetics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulgent Genetics, Inc. (FLGT)

Retrieved on: 
월요일, 11월 7, 2022
Justice, Company, Securities Exchange Act of 1934, Investment, Time, Anti-Kickback Statute, GLOBE, Exchange, Privacy Office of the U.S. Department of Homeland Security, Suite, U.S. Department of Justice Office of Legislative Affairs, Stark Law, Defendant, NASDAQ, Remuneration, Court, News, GPM, SEC, Stark, Genetics, Pharmaceutical industry, Battle of Saint-Fulgent

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Fulgent securities during the Class Period, you may move the Court no later than November 21, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Kessler Topaz Meltzer & Check, LLP Reminds Investors of November 21, 2022 Deadline in Securities Fraud Class Action against Fulgent Genetics, Inc. Investors and Urges Investors with Substantial Losses to Contact the Firm

Retrieved on: 
토요일, 11월 5, 2022
Health, Genetic testing, Disclosure, Anti-Kickback Statute, Justice, Medicare, Central District, Lead, Fraud, GLOBE, Battle of Saint-Fulgent, Reward, COVID-19, LLP, Physician, Office of Inspector General, U.S. Department of Health and Human Services, U.S. Department of Justice Office of Legislative Affairs, Stark Law, NASDAQ, District court, Remuneration, COPY, Insurance, News, SEC, Patient, Genetics, Stark, Private investigator, Pharmaceutical industry, Architecture

The action charges Fulgent with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.

Key Points: 
  • The action charges Fulgent with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.
  • As a result of Fulgents materially misleading statements and omissions to the public, Fulgent investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Fulgent investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.

FULGENT GENETICS, INC. (NASDAQ: FLGT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulgent Genetics, Inc. (NASDAQ: FLGT)

Retrieved on: 
화요일, 11월 1, 2022
Company, Health, Central District, Disclosure, Securities Exchange Act of 1934, Genetics, District court, News, SEC, Battle of Saint-Fulgent, GLOBE, Anti-Kickback Statute, COVID-19, Physician, The Legal 500, Court, Labour government, Stark, Justice, NEW, Investment, NASDAQ, Genetic testing, Reward, U.S. Department of Justice Office of Legislative Affairs, Office of Inspector General, U.S. Department of Health and Human Services, Medicare, Remuneration, Patient, Advertising, Stark Law, Tobacco, Pharmaceutical industry, Security (finance)

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Fulgent, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
  • If you purchased Fulgent securities, and/or would like to discuss your legal rights and options please visit Fulgent Genetics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulgent Genetics, Inc. (FLGT)

Retrieved on: 
금요일, 10월 28, 2022
SEC, Company, NASDAQ, Stark Law, Remuneration, GPM, Defendant, Anti-Kickback Statute, Securities Exchange Act of 1934, Court, News, GLOBE, Exchange, Justice, Lists of schools in England, Investment, Suite, Time, Stark, Privacy Office of the U.S. Department of Homeland Security, Genetics, U.S. Department of Justice Office of Legislative Affairs, Pharmaceutical industry, Battle of Saint-Fulgent

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Fulgent securities during the Class Period, you may move the Court no later than November 21, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

FULGENT DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Fulgent Genetics, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Retrieved on: 
목요일, 10월 27, 2022
SEC, Stark Law, District court, Disclosure, NASDAQ, Medicare, Remuneration, Physician, Lead, Battle of Saint-Fulgent, Genetic testing, Anti-Kickback Statute, Patient, Health, News, GLOBE, COVID-19, Fraud, Insurance, Justice, Stark, Office of Inspector General, U.S. Department of Health and Human Services, Genetics, U.S. Department of Justice Office of Legislative Affairs, COPY, LLP, Reward, Central District, Private investigator, Pharmaceutical industry, Architecture

The action charges Fulgent with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.

Key Points: 
  • The action charges Fulgent with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.
  • As a result of Fulgents materially misleading statements and omissions to the public, Fulgent investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Fulgent investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Palantir, Fulgent, Yatsen, and Barclays and Encourages Investors to Contact the Firm

Retrieved on: 
목요일, 10월 27, 2022
PLTR, Mission statement, SEC, Company, Complaint, Federal, ADR, Prospectus, NASDAQ, Disclosure, Stark Law, Medicare, Growth, Remuneration, Government, IPO, ADS, Q2, ADR Institute of Alberta, War, Physician, Anti-Kickback Statute, Battle of Saint-Fulgent, Intelligence, Genetic testing, Annual report, Patient, Health, U.S. Securities and Exchange Commission, EPS, News, YSG, BCS, COVID-19, Federation, GLOBE, Justice, Lists of schools in England, Investment, NYSE, Stark, U.S. Department of Defense Strategy for Operating in Cyberspace, Sale, U.S. Department of Justice Office of Legislative Affairs, Reward, Security (finance), Animal, Pharmaceutical industry, Audit, Online gambling, P.C, Palantir Technologies, Barclays

The Company has two operating segments, commercial and government,with the latter primarily serving agencies in the U.S. federal government and non-U.S. governments.

Key Points: 
  • The Company has two operating segments, commercial and government,with the latter primarily serving agencies in the U.S. federal government and non-U.S. governments.
  • On May 9, 2022, Palantir issued a press release announcing its Q1 financial results and guidance for Q2.
  • For more information on the Barclays class action go to: https://bespc.com/cases/BCS
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

FULGENT GENETICS, INC. (NASDAQ: FLGT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulgent Genetics, Inc. (NASDAQ: FLGT)

Retrieved on: 
화요일, 10월 25, 2022
Company, Anti-Kickback Statute, Health, Remuneration, Labour government, NASDAQ, District court, GLOBE, Stark, Lists of schools in England, NEW, Office of Inspector General, U.S. Department of Health and Human Services, Battle of Saint-Fulgent, Reward, Medicare, COVID-19, Genetic testing, Stark Law, Disclosure, Patient, Securities Exchange Act of 1934, Investment, Central District, Lists of action films, News, SEC, Justice, Genetics, The Legal 500, Advertising, Court, Physician, U.S. Department of Justice Office of Legislative Affairs, Tobacco, Pharmaceutical industry, Online gambling, Security (finance)

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Fulgent, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
  • If you purchased Fulgent securities, and/or would like to discuss your legal rights and options please visit Fulgent Genetics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fulgent Genetics, Inc. (FLGT) Investors and Encourages Investors to Contact the Firm Before November 21, 2022

Retrieved on: 
월요일, 10월 24, 2022
Physician, Genetics, Remuneration, News, Privacy Office of the U.S. Department of Homeland Security, Anti-Kickback Statute, SEC, Douglas v. U.S. District Court ex rel Talk America, NASDAQ, Patient, Court, Justice, Kirby, U.S. Department of Justice Office of Legislative Affairs, Company, Battle of Saint-Fulgent, District court, Stark, Lists of schools in England, Genetic testing, GLOBE, Central District, Disclosure, COVID-19, Stark Law, Pharmaceutical industry, Private investigator

Investors have until November 21, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 21, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Fulgent, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulgent Genetics, Inc. (FLGT)

Retrieved on: 
금요일, 10월 21, 2022
Remuneration, Genetics, News, Time, Privacy Office of the U.S. Department of Homeland Security, Anti-Kickback Statute, SEC, NASDAQ, Court, Investment, Securities Exchange Act of 1934, Justice, U.S. Department of Justice Office of Legislative Affairs, Company, Defendant, Stark, Lists of schools in England, Exchange, GLOBE, GPM, Suite, Stark Law, Pharmaceutical industry, Battle of Saint-Fulgent

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Fulgent securities during the Class Period, you may move the Court no later than November 21, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles